U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07638371) titled 'A Study of MSK-TCR5 in People With Solid Tumor Cancers' on June 05.
Brief Summary: The purpose of this study is to test the safety of MSK-TCR5 in participants with advance solid tumor cancer that has a KRAS, HRAS, or NRAS G12D mutation.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Solid Tumor
Solid Carcinoma
Advanced Solid Tumor
Unresectable Solid Tumor
Metastatic Solid Tumor
Intervention:
BIOLOGICAL: MSK-TCR5
MSK-TCR5, created in participant-derived T cells and autologously reinfused into eligible participants following lymphodepleting chemotherapy
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Memor...